Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
News|Articles|November 1, 2019
The Future Role of 3D Printing in Personalized Medicines
Author(s)Pharmaceutical Technology Editors
On the last day of CPhI Worldwide (Thursday Nov. 7, 2019), several experts will examine the potential role of three-dimensional printing within medicines, particularly in light of the shift in the industry from volume to value.
Advertisement
On the last day of CPhI Worldwide (Thursday Nov. 7, 2019), several experts will examine the potential role of three-dimensional printing within medicines, particularly in light of the shift in the industry from volume to value.
As smaller patient populations are being addressed by companies and more personalized and complex therapeutic solutions and being favored, exploration of alternative technologies, such as 3D printing, are being explored. In the panel discussion, several experts will look at the current capabilities and future potential of 3D printing technologies, the potential impact the technology may have on personalized medicines, an overview of technologies currently available, and they will present a case study on the subject matter.
Included on the panel will be Dr. Alvaro Goyanes (FabRx), Beau Jackson (3D Printing Industry), Craig Johnston (EMAC Future Manufacturing Research Hub), Ian Rees (Medicines and Healthcare products Regulatory Agency), and Jae Yoo (Aprecia Pharmaceuticals).
Made to Order: 3D Printing for Personalized Medicines
Thursday Nov. 7, 2019
10:30–11:40
ICSE Theatre (120G43)
Advertisement
Related to this article
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Advertisement
Advertisement